

RESEARCH ARTICLE

The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology

Eric M. McDade¹  | Nicolas R. Barthélemy¹ | Guoqiao Wang¹ | Yan Li¹ |
 Yuchen Cao¹ | Brian Gordon¹ | Tammie L. S. Benzinger¹ | David Clifford¹ |
 Alison M. Goate² | Alan E. Renton² | Jason Hassenstab¹ | Jorge J. Llibre-Guerra¹ |
 Richard J. Perrin^{1,3} | Chengjie Xiong⁴ | Carlos Cruchaga⁵ | Catherine J. Mummery⁶ |
 Sarah B. Berman⁷ | James Lah⁸ | Erik D. Roberson⁹ | Christopher Van Dyck¹⁰ |
 Serge Gauthier¹¹ | Colin L. Masters¹² | Mario Masellis¹³ | Tobias Bittner¹⁴ |
 Roy Yaari¹⁵ | Jasmeer Chhatwal¹⁶ | Patricio Chrem¹⁷ | William Brooks¹⁸ |
 Kazushi Suzuki¹⁹ | Johannes J. Levin²⁰ | Mathias Jucker²¹ | John Ringman²² |
 David Wallon²³ | Takeshi Ikeuchi²⁴ | Jae-Hong Lee²⁵ | Jee Hoon Roh²⁶ |
 Peter Schofield¹⁸ | Nick C. Fox⁶ | Natalie S. Ryan⁶ | Jonathan Vöglein²⁰ |
 Celeste Karch⁵ | Laura Ibáñez^{1,5} | Gregory S. Day²⁷ | Raquel Sánchez-Valle²⁸ |
 Alisha Daniels¹ | John C. Morris¹ | Charlene Supnet-Bell¹ | Allan I. Levey⁸ |
 Randall J. Bateman¹  | The DIAN-TU Study Team and DIAN Obs Team

Correspondence

Randall J. Bateman, Washington University
 School of Medicine, Department of Neurology,
 660 S. Euclid Ave., Box 8111, St. Louis, MO
 63110.
 Email: batemanr@wustl.edu

The complete list of the DIAN-TU Study Team
 can be found here: <https://dian.wustl.edu/our-research/clinical-trial/funding/>

Funding information

NIA, Grant/Award Numbers: U01AG042791,
 U01AG042791-S1, R01AG046179,
 R01AG053267-S1, U19AG032438,
 K23AG046363, P30AG066444(pilot35.3);
 Alzheimer's Association, Grant/Award
 Numbers: DIAN-TTU-12-243040,
 SG-20-690363-DIAN, AARF-16-443265; Eli
 Lilly and Company; F. Hoffmann-La Roche Ltd.;
 Avid Radiopharmaceuticals; GHR Foundation;
 Anonymous organization; Cogstate (in-kind);
 Signant Health (in-kind); German Center for
 Neurodegenerative Diseases; Raul Carrea

Abstract

BACKGROUND: Tau-derived cerebrospinal fluid (CSF) biomarkers correlate with amyloid-beta ($A\beta$) plaques or tau tangles in Alzheimer's disease (AD). This study assessed the effects of long-term anti- $A\beta$ antibodies on amyloid plaques, tau tangles, and CSF tau species to determine the relationships between them.

METHODS: A post-hoc analysis of the DIAN-TU-001 trial (NCT01760005) examined 142 participants at risk for dominantly inherited AD randomized to solanezumab ($n = 50$), gantenerumab ($n = 52$), or placebo ($n = 40$). High-resolution mass spectrometry quantified CSF tau species over four years.

RESULTS: Phosphorylated tau (p-tau) species (153, 181, 217, 231) increased early in preclinical AD but were reduced with gantenerumab-mediated $A\beta$ plaque reduction. Nearly a decade later, MTBR-tau243 and p-tau205 increased, showing no association with $A\beta$ reduction, aligning with tau tangle pathology progression.

DISCUSSION: Initially changing soluble p-tau species track $A\beta$ plaque reduction, while ptau205 and MTBR-243 reflect tau tangle pathology, informing different pathways of therapeutic strategies.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2025 The Author(s). *Alzheimer's & Dementia* published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Institute for Neurological Research (FLENI); Japan Agency for Medical Research and Development; Korea Health Technology R&D Project, Korea Health Industry Development Institute (KHIDI); Korea Health Industry Development Institute (KHIDI); Spanish Institute of Health Carlos III; Canadian Institutes of Health Research; Canadian Consortium of Neurodegeneration and Aging; Brain Canada Foundation; Fonds de Recherche du Québec – Santé; Eisai Incorporated

KEYWORDS

amyloid beta plaque reduction, dominantly inherited Alzheimer's disease, microtubule-binding region, phosphorylated tau

Highlights

- p-tau217 and p-tau231 correlate with A β -PET and respond to A β -plaque lowering therapies.
- A β immunotherapy trials support a direct link between p-tau changes and A β plaques
- Gantenerumab reduces A β plaques but does not affect tau NFT-related biomarkers.
- Blood-based p-tau217 assays may provide a non-invasive tool to monitor A β therapies.
- MTBR-tau243 strongly correlates with tau PET and tracks NFT pathology progression.
- Further studies are needed to validate tau biomarkers for tracking NFT-targeting therapies.

1 | BACKGROUND

Recent studies in dominantly inherited Alzheimer's disease (DIAD) and sporadic AD (sAD) suggest a sequence of changes in CSF and blood tau-related measures that correlate with and bridge A β -plaque and neurofibrillary tangle pathologies.^{1–5} Relatively early increased phosphorylation of three specific sites (217, 231, and 181) correlates with A β -PET positivity, followed after by increased phosphorylation of site 205 before symptom onset; later, levels of the microtubule binding region tau 243 fragment (MTBR-tau243) and non-phosphorylated tau increase near the time of clinical symptom onset, in parallel with tau-PET signal increases.^{1,6–8}

The initial rise of soluble phospho-tau, decades before the expected onset of clinical symptoms and years before substantial neurofibrillary tangles (NFT) are present, has generated uncertainty about the clinical and pathological meaning of the initial phospho-tau species.^{9,10} Soluble p-tau217, p-tau231 and p-tau181 species seem to correlate more closely with A β -plaque pathology than with hyperphosphorylated NFT pathology. Related to this, A β -plaque-lowering therapies appear to reduce levels of some blood and CSF phospho-tau species.^{11–16} Clearly, natural history and interventional studies suggest causal links between the increase in certain soluble phospho-tau measures and A β -plaque pathology. However, a comprehensive assessment of soluble phospho-tau levels before and after removing aggregated A β is needed to validate which phospho-tau isoforms are markers of A β -plaque pathology vs. tau tangle pathology.

The identification of soluble tau related biomarkers that rise in parallel with NFT pathology supports the original notion that levels of some forms of cerebrospinal fluid (CSF) tau reflect the release of aggregated tau pathology, rather than a response to established A β -plaque pathology. These forms of tau include p-tau205, and fragments that include the non-phosphorylated N-terminal domain and the cen-

tral proline-rich domain (known as total tau, t-tau), or the microtubule binding repeat (MTBR) domain.^{6,8,17,18} Compared to most phospho-tau species, p-tau205, t-tau, and MTBR-tau243 appear to have stronger correlations with clinical symptoms, cerebral atrophy, and tau-PET and, thus, may serve as a surrogate measure of clinical symptomatology. Yet, the recent studies demonstrating a decrease in A β -plaque pathology have not shown clear evidence of an influence on NFT burden by tau PET, nor evaluated these recently identified soluble tau biomarkers including relative abundance of p-tau measured as ptau/tau ratios (%p-tau). Interventional studies are needed to assess the relationships between soluble tau-related biomarkers, A β -plaques, and NFTs.

Previously, we have shown that gantenerumab (an A β -plaque targeting therapy), but not solanezumab (a A β -monomer targeted therapy) substantially reduced A β -plaques in DIAD.¹⁵ In this study, we explored the effect of both drugs on the longitudinal rate of change of multiple CSF soluble tau-related biomarkers and tau PET in individuals with DIAD in the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) 001 study. Based on our and other trial results,¹⁹ we hypothesized that A β -plaque reduction would associate with a selective normalization of *initial-changing* soluble tau biomarkers; whereas, consistent with the absence of a change in tau PET signal, *later changing* soluble tau biomarkers would be unaffected by A β -plaque reduction.

2 | METHODS

2.1 | Study participants

Eligibility criteria for the DIAN-TU-001 included participants at-risk for or known to have a DIAD mutation, who were between 15 years before or 10 years after the expected age of symptom onset,²⁰ and had a global Clinical Dementia Rating® (CDR®) of 0 (cognitively normal), 0.5

RESEARCH IN CONTEXT

1. **Systematic review:** The measurement of multiple tau-related biomarkers in observational cohorts of at-risk or symptomatic Alzheimer disease has suggested that soluble tau changes in the cerebrospinal fluid may reflect both A β -plaque and NFT tangle pathology. However, no studies have comprehensively assessed the effect of A β plaque reduction on 'early' (e.g. p-tau217) and 'late' (e.g. MTBR-tau243 and tau PET) tau biomarkers.
2. **Interpretation:** A β -plaque, but not soluble A β , reduction was associated with a distinct reduction of multiple 'early' tau biomarkers without a change in 'late' tau biomarkers. These findings support recent diagnostic criteria for Alzheimer's disease classifying early and later changes in tau-related biomarkers and suggests the use of specific phospho-tau biomarkers to monitor the response to A β -plaque lowering therapies.
3. **Future directions:** A comparative analyses of recently approved A β immunotherapies on tau-related biomarkers is needed to better understand if these soluble measures can be used to monitor long-term treatment effects.

(very mild dementia), or 1 (mild dementia).²¹ DIAD mutation carriers were randomized 3:1 to active drug (gantenerumab or solanezumab) or placebo with a minimization procedure.²² Study personnel, sponsors, and participants were blinded to treatment assignment. The DIAN Observational study (DIAN-OBS) participants included individuals of age 18 or older who were at-risk for or known to have a DIAD mutation and who had provided CSF. The DIAN-OBS and DIAN-TU studies have similar protocols, including cognitive, clinical, imaging and biomarker measures and both studies excluded participants with the APP E693Q (Dutch) mutation. Full details for the DIAN-TU-001 and DIAN-OBS are available in previous publications.^{15,23,24} The studies were conducted in accordance with the Declaration of Helsinki (version 7) and the International Conference on Harmonization and Good Clinical Practice guidelines and had ethics committee approval at each participating site. Participants provided written informed consent.

2.2 | Study design

DIAN-TU-001 was conducted at 25 sites in 7 countries from December 2012 through November 2019. The trial registration number is NCT01760005. Investigators are listed on the DIAN-TU web-page <https://dian.wustl.edu/for-investigators/diantu-investigator-resources/dian-tu-study-team/>. Biomarkers were assessed at baseline and in years 1, 2, and 4. Target drug doses were increased approximately halfway through the study as previously detailed.¹⁵ Gantenerumab was increased from 225 mg (subcutaneously, every

4 weeks) to 1200 mg in 2016. Solanezumab was increased from 400 mg (intravenously, every 4 weeks) to 1600 mg in 2017. The current CSF study includes only those participants who had CSF and brain imaging measured at all time points; the biomarker assessment between years 2 and 4 represents the time during which the drug doses were increased. This is an exploratory, post-hoc analysis that was not part of the original clinical trial statistical analysis plan. Therefore, some analyses are underpowered, and the results should be interpreted as descriptive in nature.

For the DIAN-OBS participants ($n = 247$), the study was conducted at 22 sites and data underwent yearly quality-control assessments for irregular results and missing data from January 26, 2009 to June 30, 2017.

2.2.1 | Cerebrospinal Fluid Analyses

For both DIAN-TU-001 and DIAN-OBS, CSF was collected via standard lumbar puncture procedures using an atraumatic Sprotte spinal needle (22 Ga), typically in the morning and in fasting state. DIAN-OBS CSF samples were centrifuged immediately upon collection and flash frozen, whereas DIAN-TU-001 samples were flash frozen immediately upon collection and shipped to the DIAN Biomarker Core. For the CSF tau-related analyses, each sample underwent two freeze-thaw cycles. Full details of the CSF preparation and LC-MS/MS processing have been previously outlined in detail^{5,6} and were consistent for both DIAN-OBS and DIAN-TU-001. Importantly, except for non-phosphorylated (total tau) and the microtubule binding region 243 (MTBR-tau243) concentrations, all phospho-tau measures represent the phosphorylated to unphosphorylated (pT## / T##) ratios for each modified residue or expressed as percentage (%phospho-tau).

2.2.2 | Tau and Amyloid PET Imaging

Full details on the imaging protocols for 11C-Pittsburgh Compound B (PiB) PET and 18F-AV-1451 (florbetapir) PET have been provided previously.^{25,26} Region of interest PET data were converted to regional standard uptake value ratios (SUVRs) – 47-60 minute window for PiB PET and 80-100 for florbetapir – using the cerebellar grey as a reference and were partial volume corrected using a regional spread function for each region, which when combined form a geometric transfer matrix.^{27,28} Of note, the tau PET results are derived from DIAN-TU study data only, due to limited longitudinal tau PET in the DIAN observational cohort.

2.3 | Study outcomes

The primary outcome of the DIAN-TU-001 study was the DIAN multivariate cognitive endpoint¹. For this exploratory study, the primary outcomes were the differences in the soluble CSF tau-related biomarkers in the treatment groups relative to the shared placebo group at

the end of year 4. The two active treatment arms were compared to placebo but were not directly compared to each other.

2.3.1 | Statistical Analyses

DIAN Observational Data

For each marker, the standardized mean value for mutation carriers (MCs) were estimated at each estimated years to symptom onset (EYO) point using linear mixed effects (LME) models using only baseline data, then plotted over EYO. These values were transformed into a value scaled from 0-100 (see below) to better project the magnitude of change across the disease spectrum. The LME models included the fix effects of mutation status (MC vs. non-carrier [NC]) and baseline EYO. All possible two-way interaction terms along with second and third order of EYO terms were examined to reach a final model that fit the data well for each marker. A random effect was also included to account for the family affiliation.

To evaluate the biomarker abnormality rate across EYO, percentage of abnormality for each biomarker was calculated by every five-year EYO bin (i.e. -15 to -11, etc.). The 95th percentile of the NC group was set as abnormality cutoff for all measurements except for CSF A β 42/40 where 5th percentile (lower ratio is more advanced disease) was used as the cutoff for abnormality.

DIAN-TU Data

For the trial data, which had protocol specific biomarker collection intervals, a mixed model for repeated measures (MMRM) was employed to estimate the change from baseline within each group and to compare differences between these changes. The MMRM analysis incorporated the treatment group (including either treatment group and the shared placebo group), baseline values, post-baseline visit times as categorical values, and the interaction between visit times and treatment as fixed effects; and employed an unstructured covariance matrix. We have recently developed a method to standardize different biomarkers to a scale of 0-100, called CentiMarker²⁹ (similar to the Centiloid scale,³⁰ using the 95th percentile of the greatest abnormal values for all MCs and the mean from the NCs. This method provides a way of quantifying the change for each biomarker in a similar scale to better interpret the magnitude of drug effects on each biomarker. To evaluate the correlation between amyloid PiB-PET or tau PET and each soluble biomarker, Spearman correlations were computed based on the individual annual rate of change estimated using the least squares method. This method was chosen due to the relatively small sample size of the trial as opposed to a bivariate mixed model which could be more subject to model convergence issues.

To visualize the drug effect of gantenerumab on the normal disease progression pattern of the soluble tau biomarkers and amyloid and neurodegeneration, LOESS curves were generated over cognition-adjusted EYO for gantenerumab-treated MCs, a combined MC group of placebo and solanezumab and NCs. To more intuitively compare disease progression patterns across different biomarkers, each was standardized to a scale of 0-100, called CentiMarker²⁹ using the 95th

percentile of the greatest abnormal values for all MCs and the mean from the NCs. EYO was adjusted using the baseline values of International Shopping List Test-Delayed Recall and Digit Symbol Substitution Test, employing a simplified disease progression model based on cross-sectional data.³¹ This adjusted EYO³¹ can more accurately delineate the disease progression pattern compared to an unadjusted EYO (calculated using only mutation and familial information,³² and is referred to as the cognition adjusted EYO. Because the adjustment utilized only baseline values, inclusion of two endpoints in the model was necessary for identifiability. Although any two endpoints can meet the model requirement, these ones were selected due to their greater sensitivity to disease severity and amyloid levels.³³

3 | RESULTS

Participant demographics and values of the key biomarker measurements are listed in Table 1.

3.1 | Temporal ordering of soluble CSF tau biomarkers

Our previous study from the natural history population⁵ suggested an ordering of changes in phospho-tau and total tau levels in the progression of disease including pT217/T217, pT181/T181, and pT205/T205. Here we expand on the order and magnitude of changes by including the pT153/T153, pT231/T231, and MTBR-tau243 in the DIAN-OBS cohort, Figure 1A. The figure highlights a near decade difference between the time that amyloid PET, pT153/T153, pT231/T231, pT217/T217 and pT181/T181 rise substantially in MCs, and the time when CSF pT205/T205, total tau, and MTBR-tau243 increase. Further, using 5-year time bins to track stage of disease, we assessed the proportion of MCs who had abnormal levels for each CSF tau-related biomarker, amyloid PET, Figure 1B. In alignment with the temporal pattern identified in Figure 1A, we found that there were consistencies between the proportion of MCs who had abnormal levels of specific phospho-tau ratios and amyloid PET, which were sequentially followed by increases in the proportion of MCs with abnormal levels of pT205/T205, MTBR-tau243 and CSF tau as the age of symptom onset approached; specifically, 50% of MCs had abnormal pT217/T217 levels between 20 to 15 years before symptom onset (EYO -20 to -15), whereas 50% of MCs had abnormal pT205/T205 and MTBR-tau243 between 10 to 5 years before symptom onset (EYO -10 to -5), a 10 year difference. Subsequently, we classify these groups of soluble tau biomarkers into amyloid-related CSF tau biomarkers versus tau tangle-related CSF tau biomarkers.

Based on these findings that indicate a temporal ordering of soluble tau biomarkers and distinct associations with A β -PET, we then explored the effect of amyloid targeting therapies on these soluble tau measures to better determine relationships of soluble CSF tau biomarkers with amyloid plaque and NFT pathologies.

TABLE 1 Clinical Dementia Rating and biomarker values at trial baseline by randomization.

	Active gantenerumab <i>n</i> = 52	Active solanezumab <i>n</i> = 50	Shared placebo <i>n</i> = 40
CDR 0 (<i>n</i> (%))	31 (60)	30 (60)	22 (55)
CDR > 0 (<i>n</i> (%))	21 (40)	20 (40)	18 (45)
pT153/T153	0.16 ± 0.08	0.18 ± 0.08	0.17 ± 0.08
pT181/T181	35.92 ± 8.83	38.23 ± 10.41	36.43 ± 9.25
pT205/T205	1.16 ± 0.52	1.24 ± 0.53	1.23 ± 0.60
pT217/T217	12.56 ± 7.03	14.25 ± 8.04	12.90 ± 6.93
pT231/T231	19.15 ± 12.22	21.89 ± 11.67	19.63 ± 8.81
MTBR-tau243 ng/ml	0.73 ± 0.79	0.66 ± 0.58	0.57 ± 0.46
PiB-PET Composite (Centiloid)	64.8 ± 51.9	65.2 ± 53.6	64.3 ± 50.1
Tau PET SUVR Summary Region	1.63 ± 0.60	2.64 ± 1.36	2.04 ± 1.12
Hippocampal Volume (mm ³)	7933 ± 1154	8238 ± 1342	8026 ± 1390

Abbreviations: CDR, Clinical Dementia Rating; MTBR, Microtubule binding region; PiB, Pittsburgh compound B; SUVR, Standard Uptake Volume Ratio.




FIGURE 1 Soluble tau biomarkers track disease progression in Dominantly inherited Alzheimer disease natural history cohort. (A) mean cross-sectional standardized values (y-axis) for soluble tau-related biomarkers (in CentiMarkers), clinical dementia rating sum of boxes (CDR-SB) and amyloid PET for MCs across the estimated year of onset (EYO) (x-axis). (B) percentage (y-axis) of MCs with abnormal levels (greater than 2 SD above mean of NC) of soluble tau-related biomarkers, CDR-SB and amyloid PET across the EYO (x-axis) in 5-year intervals.

3.2 | Effects of Aβ-PET change on soluble CSF tau related biomarkers

Because we previously demonstrated a substantial Aβ-plaque lowering effect by PET of gantenerumab,¹⁵ we first assessed the changes in each of the CSF tau biomarkers in the gantenerumab treated group, compared to placebo-treated MCs, using a MMRM analysis at each time-point of CSF collection, Figure 2. Following gantenerumab treatment, phospho-tau measures from the amyloid-related CSF tau biomarkers had the most consistent reduction with Aβ-PET. Tau tangle-related CSF tau biomarkers were unchanged despite the significant reduction of Aβ-PET. Solanezumab treatment was not associated with differences in PiB PET levels or any of the CSF tau related biomarkers relative to the placebo group, apart from a higher level of MTBR-tau243 in the solanezumab group compared to placebo.

We next assessed the association between the change in Aβ-PET and the change in each of the CSF tau biomarkers by assessing the correlations between the annual rates of change using the combined data from all three groups (Figure 3). Consistent with the temporal association of Aβ-PET increase and the amyloid related CSF tau biomarkers, we found that the rate of change of the amyloid-related CSF tau biomarkers correlated with changes in Aβ-PET (correlation range -pT217/T217 $\rho = 0.50$, [95% CI 0.30 - 0.66], $p < 0.0001$ to pT231/T231 $\rho = 0.35$, [95% CI 0.13 - 0.54], $p < 0.0027$); whereas the tau tangle-related CSF tau biomarkers rates of change had no association with change in Aβ-PET (correlation range pT205/T205 $\rho = 0.14$, [95% CI -0.10 - 0.36], $p < 0.2531$ to MTBR-tau243 $\rho = 0.15$, [95% CI -0.09 - 0.38], $p < 0.2018$).

Together, these findings show that the pathological accumulation and treatment-associated reduction of Aβ-plaques with the levels of




FIGURE 2 Gantenerumab and solanezumab treatment has distinct effects on amyloid PET and tau biomarkers. Estimated mean change in CentiMarkers from baseline with 95% confidence intervals for the treatment (gantenerumab (blue), solanezumab (red)) and shared placebo groups using MMRM analyses. (A, B) Estimated mean change from baseline in amyloid (PiB) PET and Tau-PET for gantenerumab. (C, D) Estimated mean change from baseline in %phospho-tau153. (E, F) Estimated mean change from baseline in %phospho-tau181. (G, H) Estimated mean change from baseline in %phospho-tau205. (I, J) Estimated mean change from baseline in %phospho-tau217. (K, L) Estimated mean change from baseline in %phospho-tau231. (M, N) Estimated mean change from baseline in MTBR-tau243. (O, P) Estimated mean change from baseline in total tau (Lumipulse immunoassay). Sample sizes at yearly assessments are listed below the x axes. Each drug group was compared to the shared placebo group independently using the MMRM model. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

phosphorylation at specific sites in soluble CSF tau are linked and suggest that pT153/T153, pT231/T231, pT217/T217 and pT181/T181 ratios may serve as surrogate markers of A β -plaque pathology in the context of AD amyloid plaque removal.

3.3 | Change in tau PET and soluble CSF tau biomarkers

Recent biomarker studies of tau PET and soluble tau species in sAD suggest that pT205/T205 and MTBR-tau243 are more closely correlated with NFT burden than pT217/T217 and other amyloid-related CSF tau biomarkers.^{1,6,8,17,18} Therefore, we assessed the relationship

between longitudinal rates of change for each of the soluble tau-biomarkers and tau PET (Figure 3). We found the strongest positive correlations with tau PET change were with the change in the tau tangle-related CSF tau biomarkers: CSF MTBR-tau243 ($\rho = 0.48$, CI [0.28, 0.64] $p < 0.0001$), followed by pT205/T205 ($\rho = 0.22$, CI [-0.02, 0.43] $p = 0.067$). For the amyloid-related CSF tau biomarkers, we found no associations or a negative correlation which was greatest for pT181/T181 ($\rho = -0.40$, CI [-0.58, -0.19] $p = 0.0004$) and pT231/T231 ($\rho = -0.25$, CI [-0.46, -0.02] $p = 0.0314$), indicating reduction of amyloid-related CSF tau biomarkers by gantenerumab despite tau PET increases at later stages. These results further support the independence of tau tangle-related CSF tau biomarkers, particularly MTBR-tau243, with amyloid plaque amounts and removal, while hav-




FIGURE 3 Change in CSF tau biomarkers and PET measures of tau and amyloid-beta show distinct relationships. Correlation (ρ) between the estimate annual rate of change in amyloid PiB-PET (blue) or tau PET (green) and in each tau biomarker. %phospho-tau153 and amyloid PiB-PET ($\rho = 0.37$, CI [0.15, 0.56] $p = 0.001$) and tau PET ($\rho = -0.08$, CI [-0.31, 0.16] $p = 0.52$); %phospho-tau181 and amyloid PiB-PET ($\rho = 0.45$, CI [0.24, 0.62] $p < 0.0001$) and tau PET ($\rho = -0.40$, CI [-0.58, -0.19] $p < 0.001$); %phospho-tau205 and amyloid PiB-PET ($\rho = 0.14$, CI [-0.10, 0.36] $p = 0.25$) and tau PET ($\rho = 0.22$, CI [-0.02, 0.43] $p = 0.07$); %phospho-tau217 and amyloid PiB-PET ($\rho = 0.50$, CI [0.30, 0.66] $p < 0.0001$) and tau PET ($\rho = -0.17$, CI [-0.39, 0.06] $p < 0.15$); %phospho-tau231 and amyloid PiB-PET ($\rho = 0.35$, CI [0.13, 0.54] $p = 0.0027$) and tau PET ($\rho = -0.25$, CI [-0.46, -0.02] $p = 0.03$); MTBR-tau243 and amyloid PiB-PET ($\rho = 0.15$, CI [-0.09, 0.38] $p = 0.2018$) and tau PET ($\rho = 0.47$, CI [0.28, 0.64] $p < 0.001$); total tau and amyloid PiB-PET ($\rho = 0.23$, CI [-0.02, 0.45] $p = 0.06$) and tau PET ($\rho = 0.1$, CI [0.15, 0.33] $p = 0.44$).

ing strong relationships with NFT tau pathology. The disassociation between amyloid-related CSF tau biomarkers and tau PET indicates these A β -PET associated soluble tau biomarkers, including p-tau217 phosphorylation, are not fully causally related with tau PET NFT pathology.

3.4 | Gantenerumab effect on tau-related disease progression

Lastly, as EYO was utilized to explore how fluid tau biomarkers change over the disease course (Figure 1), we next assessed how the treatment effect of gantenerumab changed this disease progression trajectory relative to the placebo and solanezumab groups and NCs (Figure 4).

For these analyses, each measurement was scaled to a CentiMarker range.²⁹ Notably, the CentiMarker range is typically between 0 (completely normal) to 100 (highest level for symptomatic MCs). Therefore, the greater the CentiMarker change, the closer it is likely getting towards a normal value. The figure shows that for most amyloid-related CSF tau biomarkers, gantenerumab resulted in a normalization of trajectories of approximately 50% during the asymptomatic phase (EYO < 0); this effect diminished after symptom onset (EYO > 0). There was not a biologically significant effect of gantenerumab on the trajectories of the tau tangle-related CSF tau biomarkers, with gantenerumab treated and placebo treated participants following the same trajectories. Using this approach, we better demonstrate the magnitude of changes in these biomarkers in response to treatment, relative to normal disease progression.




FIGURE 4 Gantenerumab effects on the biomarker trajectories of DIAD. Purple hashed-dot represents mutation carrier placebo-control; blue hashed represents mutation carrier gantenerumab treated group; green solid line represents non-carrier placebo-control. EYO- estimated years to onset of symptoms; (A) PiB-PET (standard uptake value ratio (SUVR)); (B) Tau-PET (SUVR), (C) hippocampal volume (based on MRI) mm³; (D) %phospho-tau153; (E) %phospho-tau181; (F) %phospho-tau205; (G) %phospho-tau217; (H) (G) %phospho-tau231; (I) Microtubule binding region (MTBR)- tau243; (J) total tau level.

4 | DISCUSSION

The co-development of effective A β -plaque lowering therapies and methods for comprehensively measuring soluble tau proteins has provided the opportunity to validate recent natural history studies linking the two canonical pathologies of AD (A β -plaques and tau tangles). Specifically, interventional studies like this provide key information to move from association to causal relationships. In this study, we assessed the effects of both A β -plaque targeting and soluble A β -monomer targeting therapies on multiple CSF tau biomarkers. Our findings clearly indicate that increased phosphorylation of specific regions of the tau protein correlate with A β -PET in the setting of DIAD; they are temporally linked to the initial rise in A β -PET and decrease as A β -PET is pharmacologically reduced. In contrast, we confirmed the relationship between selected tau tangle-related CSF tau biomarkers, particularly MTBR-tau243 and p-tau205, and tau PET, but not amyloid PET. These findings demonstrate that amyloid-related CSF tau biomarkers phosphorylated at tau residues 181, 217, and 231 indicate the amount and change in amyloid plaques, while p-tau205 and MTBR-tau243 are biomarkers of tau NFT pathology measured by tau PET. The combination of biofluid and PET biomarkers of A β and tau, along with the selective A β -plaque reduction from gantenerumab, provides strong experimental support for recent natural history studies that suggest state dependent tau changes in AD.

Multiple natural history studies of DIAD and sAD^{1,2,4,5,7,34-37} have identified correlations between the development of A β -pathology and the increase in multiple CSF phospho-tau levels, particularly p-tau217 and p-tau231. Likewise, A β -lowering immunotherapy trials in sAD have demonstrated decreases in plasma measurements of p-tau181 and 217³⁸⁻⁴⁰ in parallel with reductions in A β -PET.^{15,16,41} Our current results, along A β -plaque lowering trials in sAD^{14,16,41} validate increases in p-tau217 as a marker of A β -plaque pathology as measured by PET. Although this does not mechanistically prove A β -plaques cause the elevation of amyloid-related CSF tau biomarkers, the unique association of these changes of p-tau in AD and not other proteinopathies, the temporal links with A β -plaque changes, and now the clear associations with an intervention that lowers A β -plaques, but not tau NFTs, provides strong validation for a direct link of these initial stage CSF p-tau measures and amyloid plaques. Our findings of a consistent negative association between the rate of change of amyloid-related tau biomarkers and tau PET, Figure 3, reinforces the distinction between the tau biomarkers that first emerge with A β -plaques and respond to therapies that lowers A β -plaques but have minimal effect on tau PET. The difference in the magnitude of the negative associations of the amyloid related tau biomarkers may reflect differences in the concentrations, and thus variability, and/or could also reflect differences how these biomarkers change with NFTs. There is increasing evidence that pT217 has a more dynamic relationship based on the stage of disease

-i.e. early elevation with A β -plaques, but a greater association with tau PET at later stages of disease.⁴²

The high concordance between a normal A β -PET level and a normal pT217/T217 ratio also suggests that p-tau217 could be used to monitor for an initial and substantial response to A β -plaque lowering therapies in the context of AD. This could be particularly advantageous given the availability of blood-based p-tau217 assays, and the minimally invasive nature of phlebotomy. However, recent trials in sAD that have resulted in A β -PET levels decreasing to levels near normal, have resulted in phosphorylated tau measures decreasing to approximately fifty percent of normal levels.¹⁹ Whether this discrepancy in magnitude reduction of A β -PET and soluble p-tau with amyloid immunotherapy represents a continued contribution of NFTs to all p-tau measures, or whether there are other amyloid aggregates not detectable by PET still driving p-tau phosphorylation, or longer treatment with A β -plaque lowering therapies is needed, remains to be determined. Despite the engagement of A β -monomers by solanezumab, there was no effect on any of the A β -plaque associated phospho-tau biomarkers. This, again, reinforces the unique association with initial phospho-tau biomarkers as a reaction to substantial A β -plaque pathology.

In contrast to the progress in therapies lowering A β -plaque pathology, significantly less progress has been made in identifying agents that can lower NFT pathology. An exception is recent phase 1 trial data on antisense oligonucleotide therapies.⁴³ Future studies should evaluate the potentially causal link between putative tau tangle-related CSF tau biomarkers, pT205/T205 and MTBR-tau243, and NFT (tau PET). Although neither gantenerumab nor solanezumab influenced these soluble late-stage CSF NFT pathology measures or tau PET, with the exception of a potential increase in MTBR-tau243 in solanezumab treated group, we were able to demonstrate important longitudinal associations between these tau tangle-related CSF tau biomarkers and tau PET. For all groups in this study, the correlations for the rate of change were highest between MTBR-tau243 and tau PET. Interestingly, although pT205/T205 levels increased closer to disease onset, when tau PET increases, the rate of change was not highly correlated with tau PET change. Yet, the reduction of PiB PET and pT217/T217 in the gantenerumab treated group was not replicated with pT205/T205. This suggests that the phosphorylation of T205 marks a distinct phase in the course of tauopathy in AD.^{44,45} Despite the relatively small number of individuals included in this study, the association of late-stage fluid biomarkers with tau-PET support recent cross-sectional studies from larger numbers of at-risk and symptomatic sAD.⁶

Together, these results further the concept that tau-related fluid biomarkers inform the state and stage of AD. This has resulted in different soluble tau biomarkers being included in the updated Alzheimer Association's Diagnosis and Staging of AD criteria.⁴⁶ Specifically, p-tau217 is now proposed as a core biological marker of amyloid pathology, sufficient to identify this key pathobiological process of AD. Likewise, p-tau205 and MTBR-tau243 and other soluble tau measures are included as potential markers of a later biological pathobiological stage of AD more closely associated with clinical symptoms. Additional clinical trial data from larger A β -immunotherapy trials will further validate this staging. Further work is needed with therapies that lower NFT

pathology to validate measures like MTBR-tau243 as biomarkers of tau aggregates.

An important limitation for this work is the inclusion of DIAD participants only, which may limit generalizability to sAD. However, recent analyses of these same CSF tau-related measures have identified very similar temporal associations with disease progression in sAD (amyloid- and tau-related biomarkers), and similarly strong correlations between A β -plaque or tau PET and initial- and later-stage tau biomarkers. Moreover, recent clinical trials of multiple A β -plaque lowering therapies that have evaluated soluble (plasma or CSF) phospho-tau measures have demonstrated similar associations between A β -plaque reduction and substantial reductions of initial tau biomarkers.^{11,13,16,41,47} This suggests the results from our study in DIAD are likely applicable to sAD, but analyses on the late-stage tau biomarkers are needed in sAD interventional trials that remove plaques or lower tangles, to further assess this. Another limitation of this work is the lack of plasma tau biomarkers available to assess for similarities to CSF measures. Lastly, the *post-hoc* nature of these studies and the relatively limited numbers do not support sub-group analyses, although the strong and consistent biological effects provide sufficient power for conclusions.

This study suggests that, in AD, the presence and reduction of A β -plaque pathology can be measured not only by A β specific biomarkers but certain phospho-tau biomarkers as well. The development of blood-based phospho-tau measures, like p-tau217 concentrations and ratios, offers an important opportunity to monitor the initial response to anti-A β -plaque therapies through repeated measures using non-invasive, more accessible techniques. Ongoing and future studies targeting tau pathology may clarify the associations between specific soluble biomarkers and NFTs and determine whether tau therapies could also be monitored with blood or CSF measures.

AUTHOR CONTRIBUTIONS

All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. E.M., N.B, R.J.B. contributed to the conception and design of the study; E.M., N.B, R.J.B, B.G., T.B., A.G., A.R., A.F., J.H., R.J.P., C.X., C.C., S.S., C.M., G.S., S.B., J.L., E.R., C.V.D., S.G., R.H., M.M., J.C., P.C., B.B., K.S., H.S., J.L., M.J., J.R., D.W., Y.M., T.I., J.H. L., J.H. R., P.S., R.M., N.F., J.V., C.L., J.N., M.F., E.H., G.D., R.A., R.S., J.C.M., contributed to the acquisition and analysis of data; GW, YL, YC performed the statistical analyses; E.M., N.B, G.W., Y.L., Y.C., R.J.B. contributed to the drafting the text or preparing the figures; B.G., T.B., A.G., A.R., A.F., J.H., R.J.P., C.X., C.C., S.S., C.M., G.S., S.B., J.L., E.R., C.V.D., S.G., R.H., M.M., J.C., P.C., B.B., K.S., H.S., J.L., M.J., J.R., D.W., Y.M., T.I., J.H. L., J.H. R., P.S., R.M., N.F., J.V., C.L., J.N., M.F., E.H., G.S.D., R.A., R.S., J.C.M., T.B., R.Y., J.R., C.K., L.I., A.D., C.S.B., A.L., P.R.N reviewed and edited the draft.

AFFILIATIONS

¹Department of Neurology, Washington University School of Medicine at St. Louis, St. Louis, Missouri, USA

²Ronald M. Loeb Center for Alzheimer Disease, Dept of Genetics and Genomic Sciences, and Nash Family Dept of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA

³Department of Pathology and Immunology, Washington University School of Medicine at St. Louis, St. Louis, Missouri, USA

⁴Department of Biostatistics, Washington University School of Medicine at St. Louis, St. Louis, Missouri, USA

⁵Department of Psychiatry, Washington University School of Medicine at St. Louis, St. Louis, Missouri, USA

⁶Dementia Research Centre, University College London, National Hospital for Neurology and Neurosurgery, London, UK

⁷Department of Neurology and Translational Science, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

⁸Goizueta Alzheimer Disease Research Center, Emory University, Atlanta, Georgia, USA

⁹Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA

¹⁰Department of Psychiatry, Neurology, and Neuroscience, Yale University School of Medicine, New Haven, Connecticut, USA

¹¹Department of Psychiatry, McGill Center for Studies in Aging, Montreal, Canada

¹²Florey Institute, The University of Melbourne, Melbourne, Australia

¹³Sunnybrook Research Institute, Toronto, Ontario, Canada

¹⁴F. Hoffmann-La Roche, Basel, Switzerland

¹⁵Eli Lilly and Company, Indianapolis, Indiana, USA

¹⁶Brigham and Women's Hospital, Massachusetts General Hospital, Cambridge, Massachusetts, USA

¹⁷Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI), Buenos Aires, Argentina

¹⁸Neuroscience Research Australia and University of New South Wales Medicine, Sydney, Australia

¹⁹National Defense Medical College, Japan Osaka City University, Osaka, Japan

²⁰German Center for Neurodegenerative Diseases (DZNE), German Center for Neurodegenerative Diseases (DZNE) Munich, and University Hospital Ludwig-Maximilians-Universität (LMU) Munich, München, Bavaria, Germany

²¹German Center for Neurodegenerative Diseases (DZNE), German Center for Neurodegenerative Diseases (DZNE) Tübingen, and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Baden-Württemberg, Germany

²²Department of Neurology, University of Southern California, Los Angeles, California, USA

²³CNR-MAJ, CHU Rouen, Rouen, France

²⁴Niigata University, Niigata, Niigata, Japan

²⁵Department of Neurology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea

²⁶Asan Medical Center, Seoul, South Korea

²⁷Mayo Clinic in Florida, Jacksonville, Florida, USA

²⁸Alzheimer's disease and other cognitive disorders unit. Hospital Clinic de Barcelona, FRCB-IDIBAPS, University of Barcelona, Barcelona, Spain

ACKNOWLEDGMENTS

We thank Dr. Anne Fagan for her contributions to the DIAN and DIAN-TU Biofluid Core. We gratefully acknowledge the outstanding commitment of the participants, family members and caregivers whose participation was critical to the success of the DIAN-TU trial. We thank the DIAN-TU Funding and Study Team (<https://dian.wustl.edu/our-research/clinical-trial/funding/>) for their exceptional dedication and accomplishments, which ensured the success of the trial. We thank the

DIAN-EXR and DIAN-OBS study teams for their support on recruitment and commitment to family members. We acknowledge the robust intellectual collaboration between the DIAN-TU investigators, participants and family members, F. Hoffmann-La Roche, Ltd/Genentech and Eli Lilly and Company, the DIAN-TU Pharma Consortium (<https://dian.wustl.edu/our-research/the-pharma-consortium/>), the NIH, and regulatory representatives who were critical in making this study possible. We thank the Alzheimer Association, GHR Foundation, an anonymous organization, other industry partners (Avid Radiopharmaceuticals, a wholly-owned subsidiary of Eli Lilly and Company, Signant Health and Cogstate) and regulatory representatives for their support. We also thank L. Ryan from the National Institute on Aging (NIA) for her key contributions in leadership and scientific guidance on this project. The research reported in this publication was supported by the NIA of the NIH under award nos. U01AG042791, U01AG042791-S1 (FNIH and Accelerating Medicines Partnership), R01AG046179 and R01AG053267-S1. This research was also supported by the Alzheimer Association grant number, DIAN-TTU-12-243040, Eli Lilly and Company, F. Hoffman-LaRoche Ltd, Avid Radiopharmaceuticals GHR Foundation and an anonymous organization. Cogstate and Signant Health offered in-kind support. Data collection and sharing for this project was supported by The Dominantly Inherited Alzheimer Network (DIAN, U19AG032438) funded by the National Institute on Aging (NIA), the Alzheimer Association (SG-20-690363-DIAN), the German Center for Neurodegenerative Diseases (DZNE), Raul Carrea Institute for Neurological Research (FLENI), Partial support by the Research and Development Grants for Dementia from Japan Agency for Medical Research and Development, AMED, and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), Spanish Institute of Health Carlos III (ISCIII), Canadian Institutes of Health Research (CIHR), Canadian Consortium of Neurodegeneration and Aging, Brain Canada Foundation, and Fonds de Recherche du Québec - Santé. The performance of the mass spectrometry analyses was supported by Eisai, the Alzheimer Association Research Fellowship (AARF-16-443265, N.R.B.) and the NIA (K23 AG046363, E.M.). This manuscript has been reviewed by DIAN Study investigators for scientific content and consistency of data interpretation with previous DIAN Study publications. We acknowledge the altruism of the participants and their families and contributions of the DIAN research and support staff at each of the participating sites for their contributions to this study. Part of the methodologies applied in the manuscript was developed with support from grant P30AG066444 with pilot grant number 35.3.

CONFLICT OF INTEREST STATEMENT

There are several inventions that have been filed by Washington University for patents, including "Methods of diagnosing AD with phosphorylation changes" and "Methods to detect MTBR-tau isoforms and use". These intellectual properties owned by Washington University can be or are licensed and some licensing income may be distributed to Drs. Barthelemy, Bateman, McDade and other inventors. These intellectual properties being licensed by Washington University from C2N

and currently being utilized in our research have been reviewed by the Washington University COI and ICOI committees.

All co-inventors, including some lab members, the University, and Drs. Barthélemy, Bateman, McDade could receive part of the profits from any sales of these tests by C2N, which is in the process of licensing or has licensed some IP from the University. These activities have been reviewed by Washington University's (WU) Conflicts of Interest Review Committee in accordance with WU's Research Conflicts of Interest Policy and WU's Institutional Conflict of Interest Review Committee in accordance with WU's Institutional Conflict of Interest Policy.

EMM is supported by funding from the National Institute on Aging (K23AG046363; U01AG059798), the Anonymous Foundation, GHR, the Alzheimer's Association, and institutional support. Additional research support (to the institution) was provided by Eli Lilly, Eisai, Hoffmann-La Roche, and the DIAN-TU Pharma Consortium. He has participated in speaker engagements for Eisai, Neurology Live, and Projects in Knowledge-Kaplan. Advisory board roles, consulting, and Data Safety Monitoring Board (DSMB) participation have included relationships with Eli Lilly, Alnylam, Alector, Alzamend, Sanofi, AstraZeneca, Hoffmann-La Roche, Grifols, and Merck.

YL is the co-inventor of the technology "Novel Tau isoforms to predict onset of symptoms and dementia in Alzheimer disease" which is in the process of licensing by C2N. She may receive royalties related to the licensing agreement.

NCF reports consulting fees from Biogen, Eisai, Ionis, Lilly, Roche, and Siemens – all paid to UCL; he has served on a Data Safety Monitoring Board for Biogen; he acknowledges grant support from the Alzheimer Society, Alzheimer Research UK, Rosetrees Trust, the Sigrid Rausing Trust, the UK Dementia Research Institute and the UK NIHR UCLH Biomedical Research Centre.

AER has received funding from National Institute on Aging, National Institute of Neurological Disorders and Stroke, Alzheimer Association, JPB Foundation, and Donors Cure.

RJP reports no competing interests directly relevant to this work.

JV served as a consultant for Lilly and Eisai, and received coverage for conference and travel expenses from Biogen, Eisai, the Alzheimer's Association, the Austrian Alzheimer's Society and the German Society of Nuclear Medicine.

GSD reports no competing interests directly relevant to this work. His research is supported by NIH (K23AG064029, U01AG057195, U01NS120901, U19AG032438). He serves as a consultant for Parabon Nanolabs Inc and as a Topic Editor (Dementia) for DynaMed (EBSCO). He is the co-Project PI for a clinical trial in anti-NMDAR encephalitis, which receives support from NINDS (U01NS120901) and Amgen Pharmaceuticals; and a consultant for Arialys Therapeutics. He has developed educational materials for Continuing Education Inc and Ionis Pharmaceutical. He owns stock in ANI pharmaceuticals. Dr. Day's institution has received support from Eli Lilly for development and participation in an educational event promoting early diagnosis of symptomatic Alzheimer disease, and in-kind contributions of radio-tracer precursors for tau-PET neuroimaging in studies of memory and

aging (via Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly).

JR reports no competing interests.

KS reports no competing interests.

WB reports no competing interests.

SB reports no competing interests.

TI reports no competing interests

CHvD is a consultant for Eisai, Roche, BMS, Ono, and Cerevel and receives grant support for clinical trials from Eisai, Biogen, Eli Lilly, UCB, Cerevel, Janssen, Roche, and Genentech.

JJL reports no competing interests.

CX reports no competing interests.

BG reports no competing interests.

DW reports no competing interests.

PRS reports no competing interests.

MJ reports no competing interests.

JHL reports no competing interests.

JHR reports no competing interests.

JC has served on a medical advisory board for MEDACorp

RY full time employee and minor shareholder of Eli Lilly and Co.

TB is a full time employee and shareholder of F.Hoffmann-LaRoche

TLSB has received grants or contracts from Siemens paid to her institution; consulting fees from Biogen** (\$5,000-10,000), Eli Lilly, Eisai** (\$5,000-10,000), Bristol Myers Squibb, J&J, and Merck; payment for CME activity from Medscape, PeerView, and Neurology Today; and travel reimbursement from Cedars Sinai Medical Center, Hong Kong Neurological Association and the Alzheimer's Association. She reports the following patents planned, issued or pending: US patent 16/097,457 (DIFFUSION BASIS SPECTRUM IMAGING (DBSI), A NOVEL DIFFUSION MRI METHOD USED TO QUANTIFY NEUROINFLAMMATION AND PREDICT ALZHEIMER'S DISEASE (AD) PROGRESSION), and US Patent 12,016,701 (Quantitative Differentiation of Tumor Heterogeneity Using Diffusion MR Imaging Data). She has participated in a Data Safety Monitoring Board or Advisory Board of Siemens and served as an external advisor for NIH-funded studies (no payments). She has served as the co-chair of ASNR Alzheimer's, ARIA and Dementia Study Group, and RSNA Quantitative Imaging Committee (QuIC) (all unpaid). She has served as a committee member of the American College of Radiology/ALZ NET imaging, NIH CNN Study Section Chair, and had a leadership or fiduciary role in the ACR Commission on Neurology (all unpaid). She has received technology transfer and precursors for radiopharmaceuticals from Avid Radiopharmaceuticals/Eli Lilly, LMI, and Lantheus, as well as a scanner loan from Hyperfine to her institution.

CK reports research support from Eisai.

AL co-founder EmTherapo; consulting and advisory board Cognition Therapeutics, NextSense, Cognito Therapeutics, MEPSGEN.

CC has received research support from: GSK and EISAI. CC is a member of the scientific advisory board of Circular Genomics and owns stocks. CC is a member of the scientific advisory board of ADmit.

JL reports speaker fees from Bayer Vital, Biogen, EISAI, TEVA, Zambon, Esteve, Merck and Roche, consulting fees from Axon

Neuroscience, Eisai and Biogen, author fees from Thieme medical publishers and W. Kohlhammer GmbH medical publishers and is inventor in a patent "Oral Phenylbutyrate for Treatment of Human 4-Repeat Tauopathies" (PCT/EP2024/053388) filed by LMU Munich. In addition, he reports compensation for serving as chief medical officer for MODAG GmbH, is beneficiary of the phantom share program of MODAG GmbH and is inventor in a patent "Pharmaceutical Composition and Methods of Use" (EP 22 159 408.8) filed by MODAG GmbH, all activities outside the submitted work.

AG reports serving on Scientific Advisory Boards for: Genentech and Muna Therapeutics and as a consultant for: Merck, Biogen and Voyager Therapeutics. She reports royalties for: Taconic Biosciences, Athena Diagnostics

GW reports serving on a Data Safety Committee for Eli Lilly and Company and statistical consultant for Eisai Inc. and Alektor Inc.

MM reports no competing interests.

LI reports no competing interests.

NR reports no competing interests.

RSV has served in Advisory boards Meetings for Wave Life Sciences, Ionis, UCB, Preval, Pfizer and Novo Nordisk and received personal fees for participating in educational activities from Roche Diagnostics and Neuropharma.

EDR Is an advisor for AGTC, DMC for Lilly, royalties on licensing to Genentech, owner of additional IP related to tau.

PCM reports no competing interests.

CJM reports advisory board/consultancy at Biogen, Roche, Wave, Ionis, Preval, Lilly and Eisai; Grant for BRAPIDD ultrafast MRI study Biogen; Speaker for sponsored events/honoraria from Biogen, Roche, Eisai, Ionis and Lilly.

SG reports activity as a scientific advisor to Alzheon, AmyriAD, Eisai Canada, Lilly Canada, NovoNordisk Canada, Enigma USA.

JCM reports no competing interests.

DBC is Co-Medical Director of DIAN-TU. He receives royalties from Wolters Kluwer. He serves as scientific consultant to F. Hoffmann-La Roche Ltd/Genentech, Wave Life Sciences, Excision BioTherapeutics, Atara Biotherapeutics Inc, Sanofi Genzyme, Cellevolve Bio, Inc., Seagen Inc. and ICON (Teva). He has carried out legal consulting for Lewis, Thomason, King, Krieg and Waldrop (PML) and Loughren, Loughren, Loughren Powell Gilbert LLP. He serves on the Data Safety Monitoring Board for Wave Life Sciences, Excision Biotherapeutics Inc, Sanofi, Genzyme, Atara Biotherapeutics Inc, Cellevolve Bio, Inc. G.W. serves as a consultant for Alektor and Pharmapace. He serves on the data safety monitoring board for Eli Lilly and Co.

AD reports no competing interests.

CS reports no competing interests.

RJB is Director of DIAN-TU and Principal Investigator of DIAN-TU-001. He receives research support from the NIA of the NIH, DIAN-TU trial pharmaceutical partner (Hoffman-La Roche Ltd), Alzheimer's Association, GHR Foundation, Anonymous Organization, DIAN-TU Pharma Consortium (Active: AbbVie, Biogen, BMS, Eisai, Eli Lilly & Co., Ionis, Janssen, Prothena, Roche/Genentech. Previous: Amgen, AstraZeneca, Forum, Mithridion, Novartis, Pfizer, Sanofi, United Neuroscience). He has been a scientific advisor for NAPA Advisory Council

Biogen, F. Hoffman-La Roche/Genentech Ltd, UK Dementia Research Institute at University College London and Stanford University. He has been an invited speaker for Alzheimer's Association, Duke Margolis Alzheimer's Roundtable, BrightFocus Foundation, Tau Consortium, NAPA Advisory Council on Alzheimer's Research, CTAD, FBRI, Beeson, Adler Symposium and Fondazione Prada. R.J.B. is a co-founders of C2N Diagnostics and receive income from C2N Diagnostics for serving on the scientific advisory board. Washington University has equity ownership interest in C2N Diagnostics. R.J.B. is a co-inventors of the stable isotope labeling kinetics and blood plasma assay technology licensed by Washington University to C2N Diagnostics. Through these relationships, Washington University, R.J.B. is entitled to receive royalties and/or equity from the license agreement with C2N. Author disclosures are available in the [supporting information](#).

DATA AVAILABILITY STATEMENT

The data that support the findings of this study can be requested from DIAN at <https://dian.wustl.edu/for-investigators/dian-observational-study-investigator-resources/> and Data access to DIAN-TU trial data will follow the policies of the DIAN-TU data access policy, which complies with the guidelines established by the Collaboration for Alzheimer Prevention. Patient-related data not included in the paper were generated as part of a clinical trial and may be subject to patient confidentiality. Any data and materials that can be shared will be released via a Data/Material Sharing Agreement. A link to the DIAN-TU-001 trial data website request can be accessed via: <https://dian.wustl.edu/for-investigators/diantu-investigator-resources/>

CONSENT STATEMENT

The studies were conducted in accordance with the Declaration of Helsinki (version 7) and the International Conference on Harmonization and Good Clinical Practice guidelines and had ethics committee approval at each participating site. Participants provided written informed consent.

ORCID

Eric M. McDade  <https://orcid.org/0000-0002-6764-3866>

Randall J. Bateman  <https://orcid.org/0000-0002-7729-1702>

REFERENCES

1. Salvadó G, Horie K, Barthélemy NR, et al. Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer's disease. medRxiv [Internet]. 2023. <http://medrxiv.org/content/early/2023/07/16/2023.07.14.23292650.abstract>. 2023.07.14.23292650
2. Horie K, Li Y, Barthélemy NR, et al. Change in Cerebrospinal Fluid Tau Microtubule Binding Region Detects Symptom Onset, Cognitive Decline, Tangles, and Atrophy in Dominantly Inherited Alzheimer's Disease. *Ann Neurol*. 2023;93(6):1158-1172.
3. Luo J, Agboola F, Grant E, et al. Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan. *Brain*. 2022;145(12):4459-4473.
4. Barthélemy NR, Toth B, Manser PT, et al. Site-Specific Cerebrospinal Fluid Tau Hyperphosphorylation in Response to Alzheimer's Disease Brain Pathology: not All Tau Phospho-Sites are Hyperphosphorylated. *Journal of Alzheimer's Disease*. 2022;85:415-429.

5. Barthélemy NR, Li Y, Joseph-Mathurin N, et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. *Nat Med*. 2020;26(3):398-407.
6. Horie K, Salvadó G, Barthélemy NR, et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease. *Nat Med [Internet]*. 2023;29(8):1954-1963. <https://www.nature.com/articles/s41591-023-02443-z>
7. Barthélemy NR, Saef B, Li Y, et al. CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer's disease. *Nat Aging*. 2023;3(4):391-401.
8. Chhatwal JP, Schultz AP, Dang Y, et al. Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals. *Nat Commun [Internet]*. 2020;11(1):6024. <https://pubmed.ncbi.nlm.nih.gov/33247134>
9. Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. *Alzheimers Dement*. 2018;14(4):535-562.
10. Llibre-Guerra JJ, Li Y, Schindler SE, et al. Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. *JAMA Netw Open*. 2019;2(12):e1917126.
11. Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in Early Alzheimer's Disease. *N Engl J Med*. 2021;384(18):1691-1704.
12. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: the TRAILBLAZER-ALZ 2 Randomized Clinical Trial. *JAMA*. 2023;330(6):512-527.
13. Pontecorvo MJ, Lu M, Burnham SC, et al. Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: a Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial. *JAMA Neurol*. 2022;79(12):1250-1259.
14. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. *N Engl J Med*. 2023;388(1):9-21.
15. Salloway S, Farlow M, McDade E, et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. *Nat Med*. 2021;27(7):1187-1196.
16. McDade E, Cummings JL, Dhadda S, et al. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. *Alzheimers Res Ther*. 2022;14(1):191.
17. Lantero-Rodriguez J, Montoliu-Gaya L, Benedet AL, et al. CSF p-tau205: a biomarker of tau pathology in Alzheimer's disease. *Acta Neuropathol*. 2024;147(1):12.
18. Barthélemy NR, Saef B, Li Y, et al. CSF tau phosphorylation at T217 and T205 are improved biomarkers of amyloid and tau pathology in Alzheimer disease. *Research Gate [Internet]*. 2022. <https://www.researchsquare.com/article/rs-2175929/v1>
19. Hu Y, Cho M, Sachdev P, et al. Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer's disease. *Med [Internet]*. 2024;5(10):1206-1226. doi:10.1016/j.medj.2024.08.004
20. Ryman DC, Acosta-Baena N, Aisen PS, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. *Neurology*. 2014;83(3):253-260.
21. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology*. 1993;43(11):2412-2414.
22. Taves DR. Minimization: a new method of assigning patients to treatment and control groups. *Clin Pharmacol Ther*. 1974;15(5):443-453.
23. Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *N Engl J Med*. 2012;367(9):795-804.
24. Morris JC, Aisen PS, Bateman RJ, et al. Developing an international network for Alzheimer research: the Dominantly Inherited Alzheimer Network. *Clin Invest (Lond)*. 2012;2(10):975.
25. Gordon BA, Blazey TM, Christensen J, et al. Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. *Brain*. 2019;142(4):1063-1076.
26. Benzinger TLS, Blazey T, Jack CR, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. *Proc Natl Acad Sci U S A*. 2013;110(47):E4502-9.
27. Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. *J Nucl Med*. 1998;39(5):904-911.
28. Su Y, Blazey TM, Snyder AZ, et al. Partial volume correction in quantitative amyloid imaging. *Neuroimage [Internet]*. 2015;107:55-64. <https://www.ncbi.nlm.nih.gov/pubmed/25485714>. 20141205th ed
29. Wang G, Li Y, Xiong C, et al. The CentiMarker Project: Standardizing Quantitative Alzheimer's disease Fluid Biomarkers for Biologic Interpretation [Internet]. medRxiv. 2024. Available from: <http://medrxiv.org/lookup/doi/10.1101/2024.07.25.24311002>
30. Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. *Alzheimers Dement*. 2015;11(1):1-15.e1-4.
31. Wang G, Berry S, Xiong C, et al. A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease. *Stat Med*. 2018;37(21):3047-3055.
32. McDade E, Wang G, Gordon BA, et al. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. *Neurology [Internet]*. 2018;91(14):e1295-e1306. <https://www.ncbi.nlm.nih.gov/pubmed/30217935>. 20180914th ed
33. Wang G, Li Y, Xiong C, et al. Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease. *Alzheimers Dement*. 2024;20(4):2698-2706.
34. Barthélemy NR, Bateman RJ, Hirtz C, et al. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification. *Alzheimers Res Ther*. 2020;12(1):26.
35. Luckett PH, Chen C, Gordon BA, et al. Biomarker clustering in autosomal dominant Alzheimer's disease. *Alzheimer's & Dementia*. 2023;19(1):274-284.
36. Mattsson-Carlgen N, Janelidze S, Bateman R, et al. Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau [Internet]. Research Square; 2021. <http://europepmc.org/abstract/PPR/PPR274833>
37. Mattsson-Carlgen N, Andersson E, Janelidze S, et al. Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. *Sci Adv [Internet]*. 2020;6(16):eaaz2387. <https://www.science.org/doi/10.1126/sciadv.aaz2387>
38. Janelidze S, Berron D, Smith R, et al. Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. *JAMA Neurol*. 2021;78(2):149-156.
39. Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, and longitudinal progression to Alzheimer's dementia. *Nat Med*. 2020;26(3):379-386.
40. Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. *JAMA—Journal of the American Medical Association*. 2020;324(8):772-781.
41. Shcherbinin S, Evans CD, Lu M, et al. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: the TRAILBLAZER-ALZ Randomized Clinical Trial. *JAMA Neurol*. 2022;79(10):1015-1024.
42. Salvadó G, Ossenkoppele R, Ashton NJ, et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. *EMBO Mol Med [Internet]*. 2023;15(5):e17123. doi:10.15252/emmm.202217123

43. Edwards AL, Collins JA, Junge C, et al. Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease. *JAMA Neurol*. 2023;80(12):1344-1352.
44. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. *Acta Neuropathol [Internet]*. 2002;103(1):26-35. <http://link.springer.com/10.1007/s004010100423>
45. Moloney CM, Lowe VJ, Murray ME. Visualization of neurofibrillary tangle maturity in Alzheimer's disease: a clinicopathologic perspective for biomarker research. *Alzheimer's & Dementia [Internet]*. 2021;17(9):1554-1574. <https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12321>
46. Jack CR, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: alzheimer's Association Workgroup. *Alzheimer's & Dementia [Internet]*. 2024;20(8):5143-5169. <https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.13859>
47. Ossenkoppele R, Schonhaut DR, Schöll M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.

Brain [Internet]. 2016;139(5):1551-1567. <https://academic.oup.com/brain/article/139/5/1551/2468725>

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: McDade EM, Barthélemy NR, Wang G, et al. The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology. *Alzheimer's Dement*. 2025;21:e70689. <https://doi.org/10.1002/alz.70689>